NCT01446328View on ClinicalTrials.gov

Bergen Psychosis Project 2 - The Best Intro Study

PHASE4CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

Amisulpride

Tablets, dose range 50-1200 mg/ day

DRUG

Aripiprazole

Tablets, dose range 5-30 mg/ day

DRUG

Olanzapine

Tablets, dose range 2.5-20 mg/ day

Trial Locations (4)

5223

Haukeland University Hospital, Bergen

6020

Medizinische Universität Innsbruck, Innsbruck

Unknown

Stavanger University Hospital, Stavanger

St. Olavs Hospital, Trondheim

All Listed Sponsors
collaborator

Helse Vest

OTHER

lead

Haukeland University Hospital

OTHER

NCT01446328 - Bergen Psychosis Project 2 - The Best Intro Study | Biotech Hunter | Biotech Hunter